Previous Close | 0.7568 |
Open | 0.7321 |
Bid | 0.7309 x 100 |
Ask | 0.8311 x 100 |
Day's Range | 0.7200 - 0.7600 |
52 Week Range | 0.6500 - 2.3700 |
Volume | |
Avg. Volume | 50,665 |
Market Cap | 144.14M |
Beta (5Y Monthly) | 0.80 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3800 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.91 |
Subscribe to Yahoo Finance Plus to view Fair Value for DBVT
DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript March 7, 2024 DBV Technologies S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results […]
Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the year ended December 31, 2023, of its Annual Report on Form 10-K wi
Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old)Strengthened executive leadership team in preparation for BLA submissionReported cash and cash equivalents of $141 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa